Some of the best links we picked up around the internet
By: Gorm Palmgren - May. 14, 2021
Top pick
Efficient and gentle delivery of Cas9–sgRNA RNPs into cells has been obtained by a new technology called progressive mechanoporation (PM). PM is based on a polymer biochip that contains a series of microchannels where each microchannel is narrower than the previous one. When cells are passed through these channels, pores are temporarily formed in their cell membranes. The method is also applicable for the introduction of drugs and other small molecules.
Precision BioSciences has reported first-quarter 2021 financial results and business updates. The company has begun its PBCAR19B phase 1 study on allogeneic CAR T cells and is advancing on three other phase 1/2a clinical studies. It is also about to file an IND application for treatment of R/R multiple myeloma.
Beam Therapeutics reports a substantial increase in first-quarter R&D spending of $190.1 million, up from $21.5 in 2020. The company also reported new promising data on its proprietary lipid nanoparticle (LNP) formulation and base editing programmes.
A new review in the Journal of Analysis and Testing highlights the role of nucleic acid nanotechnology in CRISP-Cas9 systems. The review addresses delivery of Cas proteins by DNA nanovehicles, conditional CRISPR-Cas system based on dynamic RNA nanotechnology, and coupling of CRISPR-Cas and DNA origami.
An article on WebMD addresses a disability activist's fear of CRISPR. Rebecca Cokley sidelines CRISPR with eugenics that has historically been embraced to weed out 'undesirable traits'. She asks if autism and a potential gay gene will be the next targets for gene editing. She also questions the distinction between disabilities and differences and points out that not all people with disabilities want to be cured.